FindTrial
Sign In

Clinical efficacy of Huangkui capsules in the treatment of targeted drug-related proteinuria in patients with hepatocellular carcinoma

Clinical efficacy of Huangkui capsules in the treatment of targeted drug-related proteinuria in patients with hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105063
Enrollment
Unknown
Registered
2025-06-27
Start date
2025-07-14
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pproteinuria

Interventions

Conventional group:None
Huangkui capsule combined group:None

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: ?1. Aged 18-85 years? (regardless of gender). 2. Pathologically confirmed HCC or HCC diagnosed according to the European association for the study of the liver. 3?. Child-Pugh class A to B?. ?4. ECOG performance status 0-1?. ?5. Unresectable. ?6. Received molecular targeted therapy?. ?7. Presented with targeted-therapy-related proteinuria? treated with Huangkui Capsule or other medications. ?8. Complete datasets? including clinical follow-up records, laboratory tests, and survival data.

Exclusion criteria

Exclusion criteria: ?1. Concomitant malignancies other than hepatocellular carcinoma or history of other malignant tumors?. ?2. Proteinuria unrelated to targeted therapy or pre-existing renal diseases?. ?3. Incomplete medical records.

Design outcomes

Primary

MeasureTime frame
Treatment efficiency;—

Countries

China

Contacts

Public ContactYan Wang

Zhongshan Hospital, Fudan University

wang.yan2@zs-hospital.sh.cn+86 158 2167 1697

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026